ARS2 Antibody

Acts as a mediator between the cap-binding complex (CBC) and the primary microRNAs (miRNAs) processing machinery during cell proliferation. Contributes to the stability and delivery of capped primary miRNA transcripts to the primary miRNA processing complex containing DGCR8 and RNASEN, thereby playing a role in RNA-mediated gene silencing (RNAi) by miRNAs. Binds capped RNAs (m7GpppG-capped RNA); however interaction is probably mediated via its interaction with NCBP1/CBP80 component of the CBC complex. Involved in cell cycle progression at S phase. Does not directly confer arsenite resistance but rather modulates arsenic sensitivity.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: IF/IHC.

Showing Publications 1 - 2 of 2.

Publications using NBP2-15473	Applications	Species
Shankar K. Revu, Wenjuan Yang, Dhivyaa Rajasundaram, Alexander Brady, Saikat Majumder, Sarah L. Gaffen, William Hawse, Zongqi Xia, Mandy J. McGeachy Human IL-17A protein production is controlled through a PIP5K1 alpha -dependent translational checkpoint Science signaling 2024-02-21 [PMID: 37874883]
Ke X, Pang Y, Chen K et al. Knockdown of arsenic resistance protein 2 inhibits human glioblastoma cell proliferation through the MAPK/ERK pathway Oncol Rep 2018-10-09 [PMID: 30542699] (IF/IHC, Human)	IF/IHC	Human

Array NBP2-15473

• ARS2 Antibodies
• ARS2 Proteins